Tara Sanft Discusses Advancements in HER2+ Treatments

Statistically and clinically meaningful improvements in invasive disease-free survival were observed among patients with hormone receptor–positive/HER2-negative early breast cancer who received ribociclib in addition to endocrine therapy.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

The FDA has granted priority review status to a breast cancer optical imaging agent, Lumisight.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA has issued a complete response letter for vic-trastuzumab duocarmazine.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.